As a charter member of the Therapeutics Development Network of the Cystic Fibrosis Foundation, the Division of Respiratory Diseases is involved in the development and early clinical trials of novel therapeutics for CF, including: A small peptide antibiotic administered via inhalationThe use of inhaled tobramycin in young childrenAn inhaled form of an anti-inflammatory cytokineAn inhaled peptide that increases epithelial cell chloride transportA novel inhaled mucolyticAn oral leukotriene receptor antagonistA novel form of pancreatic enzyme supplementationAn oral agent that increases the expression of mutant CFTR at the cell surfaceGene therapy In addition, the Division has been or is involved studies of : - Quality of life before and after lung transplantation
- Prednisone during hospitalization for an exacerbation of lung disease
- Induced sputum as an outcome measure in infants and young children
- A DHA-containing infant formula
- Once-daily v. thrice-daily tobramycin during hospitalization for an exacerbation of lung disease
- Modifier genes and their influence on the clinical severity of CF
- CF studies examining the natural history of pulmonary function in infants and young children
- Growth hormone
- The relationship of Pseudomonas aeruginosa to the severity of lung disease.
Featured researchers in the Division of Respiratory Diseases hold faculty appointments at Harvard Medical School.
| 
Respiratory Diseases
